QLSF Biotherapeutics
A South San Francisco–based immuno-oncology company developing next-generation antibody-based therapeutics focused on multispecific and bispecific modalities to target the tumor microenvironment. Research and development emphasize engineered T cell engagers, tumor-targeted cytokine fusion proteins, preclinical in vivo validation, and clinical development through Phase 1/2 with external partnering for regional development and presentations at scientific meetings.
Industries
Nr. of Employees
small (1-50)
QLSF Biotherapeutics
300 Utah Ave, Suite 130, South San Francisco, CA 94080
Patents
Products
CLEC12A-targeted T cell engager (Phase 1)
A bispecific T cell engager that redirects T cells to CLEC12A-positive acute myeloid leukemia cells; demonstrated in vitro activity and tumor suppression in xenograft models; Phase 1 clinical trial ongoing.
LY6G6D-targeted T cell engager (Phase 1)
A T cell engager targeting a GPI-anchored antigen enriched in microsatellite-stable colorectal cancer; shown activity in vitro and in vivo; Phase 1 clinical trial ongoing.
TECOS: T cell engager with co-stimulation (IND-enabling / Preclinical)
T cell engager constructs that provide both CD3 engagement and a co-stimulatory signal to enhance and sustain T cell responses; programs at IND-enabling and preclinical stages for prostate and solid tumors.
TECAD: Avidity-driven engager with co-stimulation (Preclinical)
Combines dual-antigen avidity targeting with co-stimulatory signaling to improve tumor specificity and durability of T cell activation; preclinical development.
PD-L1–targeted bispecifics with immune modulators (Phase 1/2)
Tumor-targeted bispecific antibodies combining PD-L1 blockade with co-modulatory activities (e.g., 4-1BB activation, CD47 blocking) aimed at improving therapeutic window and minimizing systemic toxicity.
Tumor-targeted IL-15 fusion protein (Phase 1)
A PD-L1–targeted IL-15 fusion designed to increase tumor accumulation and circulation half-life, shown to enhance antitumor activity and immune memory in preclinical models; Phase 1 ongoing.
CLEC12A-targeted T cell engager (Phase 1)
A bispecific T cell engager that redirects T cells to CLEC12A-positive acute myeloid leukemia cells; demonstrated in vitro activity and tumor suppression in xenograft models; Phase 1 clinical trial ongoing.
LY6G6D-targeted T cell engager (Phase 1)
A T cell engager targeting a GPI-anchored antigen enriched in microsatellite-stable colorectal cancer; shown activity in vitro and in vivo; Phase 1 clinical trial ongoing.
TECOS: T cell engager with co-stimulation (IND-enabling / Preclinical)
T cell engager constructs that provide both CD3 engagement and a co-stimulatory signal to enhance and sustain T cell responses; programs at IND-enabling and preclinical stages for prostate and solid tumors.
TECAD: Avidity-driven engager with co-stimulation (Preclinical)
Combines dual-antigen avidity targeting with co-stimulatory signaling to improve tumor specificity and durability of T cell activation; preclinical development.
PD-L1–targeted bispecifics with immune modulators (Phase 1/2)
Tumor-targeted bispecific antibodies combining PD-L1 blockade with co-modulatory activities (e.g., 4-1BB activation, CD47 blocking) aimed at improving therapeutic window and minimizing systemic toxicity.
Tumor-targeted IL-15 fusion protein (Phase 1)
A PD-L1–targeted IL-15 fusion designed to increase tumor accumulation and circulation half-life, shown to enhance antitumor activity and immune memory in preclinical models; Phase 1 ongoing.
Services
Collaborative development, strategic partnerships, and out-licensing opportunities for platform and program advancement.
Collaborative development, strategic partnerships, and out-licensing opportunities for platform and program advancement.
Expertise Areas
- Antibody engineering and multispecific design
- T cell engager development
- Tumor microenvironment–targeted therapeutics
- Preclinical in vivo pharmacology
Key Technologies
- T cell engager architectures
- Bispecific and multispecific antibodies
- Cytokine fusion proteins
- Avidity-driven dual-antigen targeting
News & Updates
Preclinical posters for TECOS and TECAD programs presented at the AACR Meeting 2025 in Chicago.
Interim Phase 1 data for the CLEC12A-targeted T cell engager presented by development partner at EHA 2024.
Phase 1 clinical results for the PD-L1–targeted 4-1BB bispecific presented by development partner at ASCO 2024.
Announcements of first patient dosed in Phase 1 studies for two T cell engager programs targeting AML and colorectal cancer (2023).
Preclinical data posters for TECAD program (MET x EGFR) and TECOS program (PSMA) presented at AACR 2025.
Research article describing generation of an anti–PD-L1–CD47 bispecific with favorable therapeutic and safety profile.
Preclinical posters for TECOS and TECAD programs presented at the AACR Meeting 2025 in Chicago.
Interim Phase 1 data for the CLEC12A-targeted T cell engager presented by development partner at EHA 2024.
Phase 1 clinical results for the PD-L1–targeted 4-1BB bispecific presented by development partner at ASCO 2024.
Announcements of first patient dosed in Phase 1 studies for two T cell engager programs targeting AML and colorectal cancer (2023).
Preclinical data posters for TECAD program (MET x EGFR) and TECOS program (PSMA) presented at AACR 2025.
Research article describing generation of an anti–PD-L1–CD47 bispecific with favorable therapeutic and safety profile.